Keybank National Association OH cut its holdings in Mylan N.V. (NASDAQ:MYL) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,498 shares of the company’s stock after selling 371 shares during the quarter. Keybank National Association OH’s holdings in Mylan N.V. were worth $252,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in MYL. BlackRock Inc. boosted its stake in Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after acquiring an additional 37,728,274 shares during the last quarter. Pzena Investment Management LLC bought a new position in Mylan N.V. in the first quarter valued at approximately $283,158,000. TIAA CREF Investment Management LLC boosted its stake in Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after acquiring an additional 2,813,653 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management bought a new position in Mylan N.V. in the second quarter valued at approximately $84,364,000. Finally, Morgan Stanley boosted its stake in Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock valued at $162,765,000 after acquiring an additional 1,888,905 shares during the last quarter. 71.97% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on MYL shares. Cowen and Company reissued a “hold” rating and set a $30.00 price target (down from $43.00) on shares of Mylan N.V. in a research report on Wednesday, August 9th. Royal Bank Of Canada reissued a “sector perform” rating and set a $32.00 price target (down from $33.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Citigroup Inc. raised shares of Mylan N.V. from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $36.00 to $42.00 in a research report on Wednesday, August 16th. Wells Fargo & Company set a $30.00 price target on shares of Mylan N.V. and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $34.00 price target on shares of Mylan N.V. and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $43.43.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/16/keybank-national-association-oh-sells-371-shares-of-mylan-n-v-myl.html.

Shares of Mylan N.V. (MYL) opened at 32.03 on Friday. The firm has a market capitalization of $17.18 billion, a price-to-earnings ratio of 25.89 and a beta of 1.31. The firm has a 50-day moving average of $32.33 and a 200 day moving average of $37.58. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period last year, the business posted $1.16 earnings per share. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. On average, equities analysts predict that Mylan N.V. will post $4.52 earnings per share for the current fiscal year.

Mylan N.V. Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.